Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals (NQ: IONS )

49.94 -0.06 (-0.12%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,191,270
Open 50.09
Bid (Size) 48.29 (1)
Ask (Size) 51.68 (1)
Prev. Close 50.00
Today's Range 49.72 - 50.47
52wk Range 32.69 - 51.89
Shares Outstanding 141,797,854
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Where Ionis Pharmaceuticals Stands With Analysts
Via Benzinga
Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies
From Praxis Precision Medicines, Inc.
Via GlobeNewswire

Performance

YTD
+32.89%
+32.89%
1 Month
+7.89%
+7.89%
3 Month
+25.51%
+25.51%
6 Month
+23.16%
+23.16%
1 Year
+31.32%
+31.32%

More News

Read More
Technical Insights for IONIS PHARMACEUTICALS INC (NASDAQ:IONS): Is a Breakout Imminent?
Via Chartmill
Cathie Wood's Ark Invest Goes Shopping For Moderna Stock — Sells DraftKings Shares Amid Quarterly Rise In Revenue, EPS Beat
Via Benzinga
Analyst Expectations for Ionis Pharmaceuticals's Future
Via Benzinga
Analyst Expectations for Ionis Pharmaceuticals's Future
Via Benzinga
Cathie Wood-Led Ark Invest Sells Over $6.5M Worth Of Tesla Stock, What's Going On?
Via Benzinga
Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges
Via Benzinga
Why Ionis Pharmaceuticals Stock Popped Today
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023
Via Benzinga
Ionis Pharmaceuticals' Rare Metabolic Disorder Candidate Poised To Become New Standard Treatment, Study Shows Encouraging Action
Via Benzinga
Ionis Climbs On Late-Stage Trial Results For Body Fat Disorder
Via Investor's Business Daily
Ionis Pharmaceuticals Inc. (NASDAQ: IONS) Highlighted for Surprising Price Action
Via Investor Brand Network
The 7 Most Hated Stocks by Institutional Traders
Via InvestorPlace
Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope
Via Benzinga
Cathie Wood Buys Shares Of Pacific Biosciences, Reduces Exposure To DraftKings And Genius Sports
Via Benzinga
Analyst Upgrades Ionis Pharmaceuticals To Buy Amid Key Pipeline Developments: Eplontersen And Donidalorsen Show Promising Outlook
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
Via Benzinga
Apple To Rally Over 12%? Here Are 10 Other Analyst Forecasts For Monday
Via Benzinga
BridgeBio Launches 64% Higher, Pulling Alnylam And Ionis With It, On A 'Best-Case' In Heart Disease
Via Investor's Business Daily
Biogen Reports New Spinraza Data In Atrophy Patients After Incomplete Response To Novartis' Treatment
Via Benzinga
New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy
From Biogen Inc.
Via GlobeNewswire
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities
Via Talk Markets
Eli Lilly Just Lent Its Big Pharma Cachet To Verve's Nascent Gene-Editing Program For $60 Million
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.